Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company focused on vaccines, using a platform that combines protein-based nanoparticles with its proprietary Matrix-M® adjuvant. News about Novavax often centers on its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, its broader infectious disease pipeline, and the progress of key partnerships and collaborations.
Recent announcements highlight Novavax’s collaboration and license agreement with Sanofi, under which Sanofi has taken on lead commercial and regulatory responsibilities for Nuvaxovid in selected markets. News items cover marketing authorization transfers in the European Union and United States, milestone payments to Novavax, and Sanofi’s clinical data on combination vaccine candidates that incorporate Nuvaxovid and Matrix-M. Updates also describe regulatory approvals in markets such as Japan through partner Takeda, triggering additional milestone payments and royalty opportunities.
Investors following NVAX news will see regular coverage of quarterly financial results, revenue composition from product sales, supply sales and licensing and royalty streams, as well as information on Novavax’s site consolidation and cost footprint in Maryland. The company’s communications also describe early-stage research on vaccine candidates for shingles, Clostridioides difficile colitis and respiratory syncytial virus combinations, and the use of Matrix-M in the R21/Matrix-M malaria vaccine developed with Serum Institute of India and Oxford University.
This page aggregates press releases, conference participation announcements, regulatory updates and other material events related to Novavax. Readers can use it to monitor developments in the company’s vaccine programs, partnership milestones, capital structure transactions and strategic transformation as disclosed in public statements.
On January 25, 2023, Novavax (NASDAQ: NVAX) announced the grant of inducement awards to its new President and CEO, John C. Jacobs, effective January 23, 2023. The awards include a non-qualified stock option for 290,700 shares at an exercise price of $11.92, with a ten-year term and a vesting schedule based on continued employment. Additionally, 249,590 restricted stock units will vest over three years. This action is in compliance with Nasdaq Listing Rule 5635(c)(4) and the 2023 Inducement Plan, reflecting the company's commitment to attracting top talent as it continues to develop next-generation vaccines.
Novavax, Inc. (NVAX) announced that its partner SK bioscience has received expanded approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid (NVX-CoV2373) to be used as a booster for COVID-19 in adults aged 18 and older. This decision follows prior recommendations from the Korean Centers for Disease Control and Prevention. The approval is based on data from Novavax's Phase 2 trials, which showed increased immune responses following the booster. Nuvaxovid is now authorized for use as a booster in over 35 countries. The vaccine utilizes Novavax's proprietary technology and is under review in additional markets for further indications.
Novavax, Inc. (Nasdaq: NVAX) announced that John C. Jacobs will succeed Stanley C. Erck as President and CEO effective January 23, 2023. Erck will assist in the leadership transition for 15 months. Jacobs brings over 25 years of industry experience, having led Harmony Biosciences through its IPO and FDA product approval. Under Erck's leadership since 2011, Novavax launched its COVID-19 vaccine in over 40 countries. The company is positioned to continue its strategic development with multiple vaccine candidates in progress.
Novavax, Inc. (Nasdaq: NVAX) has initiated a Phase 2 trial for its COVID-19-Influenza Combination (CIC) vaccine and a stand-alone influenza vaccine. This dose-confirming trial will assess safety and immunogenicity in adults aged 50-80 and aims to enroll around 2,300 participants across Australia and New Zealand. Initial results are expected mid-2023, which will guide the Phase 3 trials. The company draws optimism from earlier positive results from the Phase 1/2 trial, focusing on providing better protection against influenza and COVID-19, especially for older adults.
On December 20, 2022, Novavax (Nasdaq: NVAX) completed a $150 million offering of 5.00% Senior Convertible Notes due 2027, with an additional $25.25 million purchased by initial buyers. Also, a public offering of 7,475,000 shares of common stock raised $74.75 million. The combined gross proceeds from both offerings amount to $250 million. The Notes are convertible at $12.50 per share, representing a 25% conversion premium. Novavax estimates net proceeds of approximately $166.3 million from the Notes and $69.8 million from the stock offering, earmarked for corporate purposes.
Novavax, Inc. (Nasdaq: NVAX) announced a $150 million offering of 5.00% convertible senior notes due 2027, with an option for initial purchasers to buy an additional $25.25 million. The notes will accrue interest semi-annually and are redeemable post December 22, 2025. Concurrently, a public offering of 6,500,000 shares of common stock at $10.00 per share, totaling $65 million, has been priced. Proceeds will support global launches, operational costs, and R&D. Offerings are expected to close on December 20, 2022.
Novavax, Inc. (Nasdaq: NVAX) has announced the pricing of a public offering of 6,500,000 shares of common stock at $10.00 per share, raising approximately $65 million. The underwriters have a 30-day option to buy an additional 975,000 shares. Concurrently, Novavax priced $150 million in convertible senior notes due in 2027. The net proceeds will be used for general corporate purposes, including the global launch of Nuvaxovid and repaying outstanding senior notes. Both offerings are expected to close on December 20, 2022, subject to customary conditions.
Novavax, Inc. (Nasdaq: NVAX) announced a proposed underwritten public offering of up to $125 million in common stock, with an option for underwriters to purchase an additional $18.75 million. Concurrently, the company plans to offer $125 million in convertible senior notes due 2027, also with a $18.75 million additional option. The proceeds will be used for general corporate purposes, including the global launch of Nuvaxovid, working capital, R&D, and debt repayment.
Novavax, Inc. (Nasdaq: NVAX) announced a proposed offering of $125 million in convertible senior notes due 2027. These notes will be sold to qualified institutional buyers under Rule 144A. The company may also offer up to $125 million in common stock, with an additional $18.75 million option for both offerings. Proceeds will support general corporate purposes, including the launch of Nuvaxovid and repay existing convertible notes. The offering is not contingent on the other, and the financial terms will be set at pricing.
On December 7, 2022, Novavax, Inc. (Nasdaq: NVAX) announced that Health Canada has approved the Nuvaxovid COVID-19 Vaccine for use as a primary series for adolescents aged 12 to 17. This approval is based on data from the Phase 3 PREVENT-19 trial, demonstrating a clinical protective efficacy of 79.5%, particularly against the Delta variant. Nuvaxovid is already authorized in over 10 markets globally, including the U.S. and European Union. The vaccine will be manufactured in Montreal, with engineering runs completed and production of qualification batches expected to start in early 2023.